Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - Supernus Pharmaceuticals is preparing for significant developments in 2025 and beyond, particularly with the acquisition of Sage Therapeutics and new product launches [3] Group 1: Company Developments - The company has achieved FDA approval for new products in July 2025, marking a pivotal moment in its growth strategy [3] - The acquisition of Sage Therapeutics is highlighted as a key accomplishment that will influence the company's positioning for 2026 [3] Group 2: Leadership and Presentation - Glen Santangelo from Barclays Bank PLC is the analyst responsible for the specialty pharmaceutical sector and is leading the presentation [2] - Jack Khattar, the President and CEO of Supernus Pharmaceuticals, is present to discuss the company's recent achievements and future plans [2]